PreciseDx
Innovating breast cancer diagnostic testing with PreciseBreast
Innovating breast cancer diagnostic testing with PreciseBreast
PreciseDx is a health care startup founded in 2019 with the slogan "Innovating oncology diagnostics through the power of AI." The company leverages Artificial Intelligence (AI) and the patented Morphology Feature Array® (MFA) for revolutionary, morphology-driven disease analysis. Their aim is to provide access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.
The most recent milestone for PreciseDx was a $20.70M Series B investment on 22 August 2024. The investors in this round included Eventide Asset Management, LabCorp, Quest Diagnostics, and GenHenn Capital Venture. This investment signifies a strong show of support from major players in the industry, underlining the potential and value seen in PreciseDx's approach to advancing oncology diagnostics.
PreciseDx's innovative use of AI and morphology-driven analysis sets them apart in the field of oncology diagnostics, positioning the company as a key player in providing crucial insights and intelligence for more effective decision-making in cancer care. The latest investment further solidifies their standing in the industry and paves the way for continued advancements in this critical area of healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $20.70M | 4 |
|
22 Aug 2024 |
| Series B | $20.72M | - | 01 Apr 2024 | |
| Series A | $10.75M | 4 |
|
11 Jan 2022 |
We care about your data, and we'd love to use cookies make your experience better.
